Teva (Page 4 sur 4)

C'est sectoriel, Mylan est en hausse aussi.

J'en avais repris hier à 32,59$.

U.S. court rejects Teva's patent-infringement claims on Copaxone
 
01:46 (31/01) - Source: RTRS

    Jan 30 (Reuters) - Teva Pharmaceutical Industries Ltd
    TEVA.N  said on Monday a U.S. court rejected four of
the Israel-based drugmaker's claims of patent infringement on
its top-selling multiple sclerosis treatment.
    The rejection comes four months after U.S. patent officials
invalidated three patents on its drug Copaxone, in response to
challenges by pharmaceutical company Mylan NV   , which has
been trying to market a generic version of the drug.
 
    All asserted claims of Teva were invalid, the U.S. District
Court Of Delaware said in a ruling on Monday.
    The patents, which expire in 2030, cover a 40-milligram
injection of Copaxone that patients administer three times a
week.
    Generics may only be sold after a drug's patents expire or
are invalidated through litigation.
    However, Teva said it planned to appeal the decision.
    U.S.-listed shares of Teva were down almost 9 percent in
after-hours trading, while Mylan's shares edged up marginally.

Teva – Un juge américain prononce la perte de quatre brevets sur la Copaxone, le taitement vedette de la sclérose en plaques commercialisé par le plus grand producteur de médicaments génériques du monde.